Cargando empresa
Keep exploring
The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And Company1,36T US$A+
JNJJohnson & Johnson688,6B US$A+
MRKMerck & Co., Inc.364,3B US$A
NVSNovartis AG306,3B US$A
AMGNAmgen Inc.251,9B US$A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Cómo gana dinero
- Sales of prescription medicines72 %
- Anti-CD20 medicine royalties and profit shares18 %
- Contract manufacturing, royalties and related revenue8 %
- Alzheimer’s medicine collaboration2 %
Los porcentajes de ingresos son estimaciones para nine months ended September 30, 2026, no cifras de un informe oficial.
Compite con
- RHHBYRoche Holding AG
Qué vende6
SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.
Mostrar 3 más
SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.
Quién se lo compra4
- Wholesale distributors buy medicines in bulk for resale; a pair of distributors together accounted for 43.9% of gross product revenue (FY 2025, high).
- Specialty pharmacies and specialty distributors handle medicines that require specific storage, delivery or patient support.
- Hospitals, clinics and physicians prescribe or administer Biogen medicines and help patients obtain them.
- Government health programs and private insurers cover or reimburse the cost of many treatments.
En qué se apoya y qué podría romperlo
De qué depende el negocio
- 1Biogen relies on collaborators for some medicines’ development, manufacturing or sales, including Eisai, Ionis, Genentech, Supernus and Samsung Bioepis.
- 2A pair of wholesale distributors accounted for 43.9% of gross product revenue (FY 2025, high).
- 3Sales depend on regulatory approval, continued patent or other market protection, and coverage and reimbursement from government programs and private insurers.
Qué podría salir mal
- 1Generic and biosimilar medicines, as well as newer competing treatments, can reduce sales or prices; generic versions of TECFIDERA and a biosimilar version of TYSABRI already compete with those products.
- 2Clinical studies can fail, take longer than planned or lead regulators to reject a medicine, limiting revenue from new products and additional uses of existing medicines.
- 3Changes to drug-price rules, insurance coverage or reimbursement can restrict patient access or lower the amount Biogen receives for its medicines.
Estados financieros completos →
Sobre Biogen Inc.
Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.
- Sede
- Cambridge, Massachusetts
- Fundada en
- 1978
- Cotiza en
- NASDAQ
- Cierre del ejercicio
- December 31
Construido a partir de los propios informes de Biogen Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.